

(12) International Application Status Report

Received at International Bureau: 19 January 2018 (19.01.2018)

Information valid as of: 11 June 2018 (11.06.2018)

Report generated on: 22 September 2019 (22.09.2019)

(10) Publication number:

WO2018/121669

(43) Publication date:

05 July 2018 (05.07.2018)

(26) Publication language:

Chinese (ZH)

(21) Application Number:

PCT/CN2017/119360

(22) Filing Date:

28 December 2017 (28.12.2017)

(25) Filing language:

Chinese (ZH)

(31) Priority number(s):

201611257037.8 (CN)

(31) Priority date(s):

30 December 2016 (30.12.2016)

(31) Priority status:

Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:

A61K 31/7068 (2006.01); A61K 31/4412 (2006.01); A61K 31/53 (2006.01); A61P 35/00 (2006.01)

(71) Applicant(s):

CHEN, Xiaohua [CN/CN]; Room 102, Unit 2, Building 5 No. 40, Majia Street, Gulou District Nanjing, Jiangsu 210009 (CN) (*for all designated states*)

(72) Inventor(s):

CHEN, Xiaohua; Room 102, Unit 2, Building 5 No. 40, Majia Street, Gulou District Nanjing, Jiangsu 210009 (CN)

(74) Agent(s):

BEIJING WITAL PATENT AGENCY CO., LTD.; LU, Weiwei Room 0549, 5th Floor, 8th Building, Jia No. 2 East Sanhuan North Road, Chaoyang District Beijing 100027 (CN)

(54) Title (EN): PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND USE THEREOF

(54) Title (FR): COMPOSITION PHARMACEUTIQUE DESTINÉE AU TRAITEMENT DU CANCER, ET UTILISATION CORRESPONDANTE

(54) Title (ZH): 一种用于治疗癌症的药物组合物及其应用

(57) Abstract:

(EN): A pharmaceutical composition and kit for treating cancer, being used to enhance anti-tumor effects of capecitabine and reduce side effects. The pharmaceutical composition comprises an anti-tumor effective amount of capecitabine, anti-tumor synergistically effective amount of gimeracil, and potassium oxonate in an effective amount for reducing side effects, and is used for treating 5-fluorouracil-sensitive mammalian tumors.

(FR): L'invention concerne une composition pharmaceutique et un kit permettant le traitement du cancer, qui sont utilisés pour augmenter les effets antitumoraux de la capécitabine et diminuer ses effets indésirables. La composition pharmaceutique comprend une quantité efficace d'un point de vue antitumoral de capécitabine, une quantité efficace d'un point de vue antitumoral synergique de gimeracil, et de l'oxonate de potassium en une quantité efficace pour diminuer les effets indésirables, et est utilisée pour traiter des tumeurs de mammifère sensibles au 5-fluorouracile.

(ZH): 一种用于治疗癌症的药物组合物和试剂盒,用于增强卡培他滨的抗肿瘤效果且降低副作用,该药物组合物包含有抗肿瘤有效量的卡培他滨、抗肿瘤增效效应有效量的吉莫斯特以及降低副作用有效量的氧嗪酸钾,用于治疗对5-氟尿嘧啶敏感的哺乳动物的肿瘤。

International search report:

Received at International Bureau: 20 March 2018 (20.03.2018) [CN]

International Report on Patentability (IPRP) Chapter II of the PCT:

Not available

(81) Designated States:

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM